학술논문

Glycemic Control and Aspirin Resistance in Patients Taking Low-Dose Aspirin for Pre-eclampsia Prevention.
Document Type
Article
Source
American Journal of Perinatology. Mar2022, Vol. 39 Issue 4, p349-353. 5p.
Subject
*GLYCOSYLATED hemoglobin
*GLYCEMIC control
*PREECLAMPSIA
*ASPIRIN
*DESCRIPTIVE statistics
*DRUG interactions
*THROMBOXANES
*SECONDARY analysis
*PHARMACODYNAMICS
Language
ISSN
0735-1631
Abstract
Objectives  To assess the association between aspirin and glycemic control in diabetic, pregnant patients, and the risk for aspirin resistance in those with poor glycemic control across gestation taking low-dose aspirin (LDA) for pre-eclampsia (PEC) prevention. Study Design  We performed a secondary analysis of samples collected during the Maternal-Fetal Medicine Units trial of LDA for PEC prevention. A subset of insulin-controlled diabetic patient samples on placebo or 60 mg aspirin daily were evaluated. Glycosylated hemoglobin was measured at randomization, mid-second trimester, and third trimester time points. Thromboxane B 2 (TXB 2) measurements were previously assessed as part of the original study. Primary outcome was the effect of LDA on glycosylated hemoglobin levels compared with placebo across gestation. Results  Levels of glycosylated hemoglobin increased across gestation in the placebo group (2,067.7 [interquartile range, IQR: 1,624.6–2,713.5 µg/mL] vs. 2,461.9 [1,767.0–3,209.9 µg/mL] vs. 3,244.3 [2,691.5–4,187.0 µg/mL]; p  < 0.01) compared with no difference in levels of glycosylated hemoglobin across gestation in the LDA group (2,186.4 [IQR: 1,462.3–3,097.7 µg/mL] vs. 2,337.1 [1,327.7–5,932.6 µg/mL] vs. 2,532.9 [1,804.9–5,511.8 µg/mL]; p  = 0.78). Higher levels of glycosylated hemoglobin were associated with increased TXB 2 levels prior to randomization (r  = 0.67, p  < 0.05). Incomplete TXB 2 was higher in pregnancies with increasing levels of glycosylated hemoglobin compared with those with decreasing levels of glycosylated hemoglobin across gestation (69.2 vs. 18.1%, p  = 0.02). Conclusion  LDA exposure may be beneficial to glycemic control in this patient population. Additionally, poor glycemic control is associated with a higher level of TXB 2 in diabetic pregnant patients on LDA. Higher doses of aspirin may be required in these patients to prevent development of PEC. Key Points Low-dose aspirin may improve glycemic control. Poor glycemic control increases risk for aspirin resistance. Higher doses of aspirin may be required for pre-eclampsia prevention. [ABSTRACT FROM AUTHOR]